I
ImmuniQ
Develops a novel method to predict patient response to immune checkpoint inhibitors in oncology.
About
ImmuniQ is an immuno-oncology company focused on improving the efficacy of immune checkpoint inhibitors. They have developed a novel method to assess the functional activity of a patient's cancer cells, aiming to predict which patients will benefit from these treatments, thereby optimizing therapeutic outcomes.
Technology stack
detected 2026-05-24Est. monthly stack spend~$70/mo
Emailnone
Comments
No comments yet. Be the first to share your take.
Frequently asked
What does ImmuniQ do?
ImmuniQ is an immuno-oncology company focused on improving the efficacy of immune checkpoint inhibitors. They have developed a novel method to assess the functional activity of a patient's cancer cells, aiming to predict which patients will benefit from these treatments, thereby optimizing therapeutic outcomes.
Where is ImmuniQ headquartered?
ImmuniQ is headquartered in Tel Aviv, Israel.
When was ImmuniQ founded?
ImmuniQ was founded in 2021.
What industry does ImmuniQ operate in?
ImmuniQ operates in Life Sciences, Oncology, Patient Care, Biotech, MedTech, HealthTech.
What is ImmuniQ's current status?
ImmuniQ's current operating status is: Inactive.